Drugging the Next Undruggable KRAS Allele-Gly12Asp

被引：24
|
作者：
Zheng, Qinheng [1 ]
Peacock, D. Matthew [1 ]
Shokat, Kevan M. [1 ]
机构：
[1] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2022年 / 65卷 / 04期
关键词：
K-RAS; BIND;
D O I：
10.1021/acs.jmedchem.2c00099
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Since its discovery as the first human oncogene in 1983, the small GTPase KRAS has been a major target of cancer drug discovery. The paper reported in this issue describes a long-awaited small molecule drug candidate of the oncogenic KRAS (G12D) mutant for the treatment of currently incurable pancreatic cancer.
引用
收藏
页码：3119 / 3122
页数：4
相关论文
共 50 条
  • [1] Drugging an undruggable pocket on KRAS
    Kessler, Dirk
    Gmachl, Michael
    Mantoulidis, Andreas
    Martin, Laetitia J.
    Zoephel, Andreas
    Mayer, Moriz
    Gollner, Andreas
    Covini, David
    Fischer, Silke
    Gerstberger, Thomas
    Gmaschitz, Teresa
    Goodwin, Craig
    Greb, Peter
    Haring, Daniela
    Hela, Wolfgang
    Hoffmann, Johann
    Karolyi-Oezguer, Jale
    Knesi, Petr
    Kornigg, Stefan
    Koegl, Manfred
    Kousek, Roland
    Lamarre, Lyne
    Moser, Franziska
    Munico-Martinez, Silvia
    Peinsipp, Christoph
    Phan, Jason
    Rinnenthal, Joerg
    Sai, Jiqing
    Salamon, Christian
    Scherbantin, Yvonne
    Schipany, Katharina
    Schnitzer, Renate
    Schrenk, Andreas
    Sharps, Bernadette
    Siszler, Gabriella
    Sun, Qi
    Waterson, Alex
    Wolkerstorfer, Bernhard
    Zeeb, Markus
    Pearson, Mark
    Fesik, Stephen W.
    McConnell, Darryl B.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (32) : 15823 - 15829
  • [2] Drugging undruggable kras: will myc do the trick?
    Der, Channing J.
    CANCER RESEARCH, 2016, 76
  • [3] Drugging the undruggable: A market readiness analysis for KRAS-G12C.
    Loupakis, Fotios
    Bloom, Kenneth Joel
    Allen, Wendy
    Scanlon, Enya
    Stacey, Isabel
    Keeling, Derry Mae
    Patel, Nital
    Clark, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
    Kale, Ramesh
    Samant, Charudatt
    Nandakumar, Krishnadas
    Pai, K. Sreedhara Ranganath
    Bhonde, Mandar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 760
  • [5] Drugging the undruggable: a computational chemist's view of KRASG12C
    Bodnarchuk, Michael S.
    Cassar, Doyle J.
    Kettle, Jason G.
    Robb, Graeme
    Ward, Richard A.
    RSC MEDICINAL CHEMISTRY, 2021, 12 (04): : 609 - 614
  • [6] KRAS G12C mutation is not undruggable anymore
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
  • [7] Drugging an undruggable pocket: The biochemical mechanism of covalent KRASG12C inhibitors
    Hansen, Rasmus
    Peters, Ulf
    Babbar, Anjali
    Chen, Yuching
    Feng, Jun
    Janes, Matthew R.
    Li, Liansheng
    Ren, Pingda
    Liu, Yi
    Zarrinkar, Patrick P.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
    Li, Hui-yu
    Qi, Wei-liang
    Wang, Yu-xiang
    Meng, Ling-hua
    GENES & DISEASES, 2023, 10 (02) : 403 - 414
  • [9] KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
    El Osta, Badi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1147 - 1151
  • [10] KRAS Mutation Allele Frequency Impacts Prognosis in Pancreatic Ductal Adenocarcinoma Using Next Generation Sequencing
    Nauheim, David O.
    Moskal, David
    Renslo, Bryan
    Jiang, Wei
    Yeo, Charles J.
    Nevler, Avinoam
    Bowne, Wilbur B.
    Lavu, Harish
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 233 (05) : S150 - S151
12345